Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer-Reference-Cited by-同舟云学术

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer

Published:2019-06 Issue:3 Volume:153 Page:555-561
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Secord Angeles Alvarez^ORCID,McCollum Michael,Davidson Brittany A.,Broadwater Gloria,Squatrito Robert,Havrilesky Laura J.,Gabel Anne C.,Starr Mark D.,Brady J. Chris,Nixon Andrew B.,Duska Linda R.

Funder

Boehringer Ingelheim

AbbVie

Amgen

Astellas Pharma Inc.

Astex Pharmaceuticals Inc.

AstraZeneca

Bristol Myers Squibb

Eisai

Endocyte

Exelixis

Incyte

Merck

PharmaMar

Prima Biomed

Roche/Genentech

TapImmune

TESARO

Acceleron Pharma

AstraZeneca/MedImmune

Eureka Therapeutics

Genentech

Leadiant Biosciences

MedPacto Inc.

Novartis

Seattle Genetics

Tracon Pharma

Duke University

AbbieVie

Millenium

Cerulean

Pfizer

Tesaro

Morab

Ludwig

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Duke University Division of Gynecologic Oncology

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference30 articles.

1. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol.. 2007;25(33):5165-71. doi:https://doi.org/10.1200/JCO.2007.11.5345. PubMed PMID: 18024863.

2. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

3. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011

4. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012

5. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol.. 2014;32(13):1302-8. doi:https://doi.org/10.1200/JCO.2013.51.4489. PubMed PMID: 24637997.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer;Gynecologic Oncology;2024-09

2. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09

3. Probiotics alleviate paraneoplastic thrombocythemia of ovarian cancer: A randomized placebo-controlled trial;Journal of Functional Foods;2024-08

4. Aberrant angiogenic signaling pathways: Accomplices in ovarian cancer progression and treatment;Cellular Signalling;2024-08

5. Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes;Pharmacological Research;2024-06